Unrelated Donor Bone Marrow Transplants for Severe Aplastic Anemia with Conditioning Using Total Body Irradiation and Cyclophosphamide

Biology of Blood and Marrow Transplantation

Volumn 13, Issue 7, 2007, Pages 863-870

  Kim, Sung Yong ^a   Lee, Jong Wook ^a   Lim, Jihyang ^a   Cho, Byung Sik ^a   Eom, Ki Seong ^a   Kim, Yoo Jin ^a   Kim, Hee Je ^a   Lee, Seok ^a   Min, Chang Ki ^a   Cho, Seok Goo ^a   Kim, Dong Wook ^a   Min, Woo Sung ^a   Kim, Chun Choo ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Aplastic anemia; Cyclophosphamide; Total body irradiation; Unrelated donor transplant

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; TACROLIMUS;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; APLASTIC ANEMIA; ARTICLE; BLADDER DISEASE; BLOOD TRANSFUSION; BONE MARROW TRANSPLANTATION; CARDIOTOXICITY; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DONOR; ENGRAFTMENT; FEMALE; GASTROINTESTINAL TOXICITY; GRAFT REJECTION; HLA TYPING; HUMAN; INCIDENCE; LIVER TOXICITY; LUNG TOXICITY; MALE; NEPHROTOXICITY; NEUROTOXICITY; OVERALL SURVIVAL; PROBABILITY; RECIPIENT; SEROLOGY; STOMATITIS; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; ANEMIA, APLASTIC; BONE MARROW TRANSPLANTATION; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT VS HOST DISEASE; HUMANS; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TISSUE DONORS; WHOLE-BODY IRRADIATION;

EID: 34250369700     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2007.03.013     Document Type: Article

References (34)

1. Margolis D.A., and Casper J.T. Alternative-donor hematopoietic stem-cell transplantation for severe aplastic anemia. Semin Hematol 37 (2000) 43-55
2. Horowitz M.M. Current status of allogeneic bone marrow transplantation in acquired aplastic anemia. Semin Hematol 37 (2000) 30-42
3. Kernan N.A., Bartsch G., Ash R.C., et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med 328 (1993) 593-602
4. Hows J.M., Yin J.L., Marsh J., et al. Histocompatible unrelated volunteer donors compared with HLA nonidentical family donors in marrow transplantation for aplastic anemia and leukemia. Blood 68 (1986) 1322-1328
5. Kojima S., Matsuyama T., Kato S., et al. Outcome of 154 patients with severe aplastic anemia who received transplants from unrelated donors: the Japan Marrow Donor Program. Blood 100 (2002) 799-803
6. Altes A., Remacha A.F., Sureda A., et al. Iron overload might increase transplant-related mortality in haematopoietic stem cell transplantation. Bone Marrow Transplant 29 (2002) 987-989
7. Kaminski E.R., Hows J.M., Goldman J.M., and Batchelor J.R. Pretransfused patients with severe aplastic anaemia exhibit high numbers of cytotoxic T lymphocyte precursors probably directed at non-HLA antigens. Br J Haematol 76 (1990) 401-405
8. Deeg H.J., O'Donnell M., Tolar J., et al. Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy. Blood 108 (2006) 1485-1491
9. Bearman S.I., Appelbaum F.R., Buckner C.D., et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 6 (1988) 1562-1568
10. Storb R., Deeg H.J., Whitehead J., et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 314 (1986) 729-735
11. Nash R.A., Antin J.H., Karanes C., et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 96 (2000) 2062-2068
12. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 15 (1995) 825-828
13. Shulman H.M., Sullivan K.M., Weiden P.L., et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 69 (1980) 204-217
14. Socie G., Henry-Amar M., Bacigalupo A., et al., European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party. Malignant tumors occurring after treatment of aplastic anemia. N Engl J Med 329 (1993) 1152-1157
15. Deeg H.J., Socie G., Schoch G., et al. Malignancies after marrow transplantation for aplastic anemia and fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. Blood 87 (1996) 386-392
16. Deeg H.J., Amylon I.D., Harris R.E., et al. Marrow transplants from unrelated donors for patients with aplastic anemia: minimum effective dose of total body irradiation. Biol Blood Marrow Transplant 7 (2001) 208-215
17. Deeg H.J., Anasetti C., Petersdorf E., et al. Cyclophosphamide plus ATG conditioning is insufficient for sustained hematopoietic reconstitution in patients with severe aplastic anemia transplanted with marrow from HLA-A, B, DRB matched unrelated donors. Blood 83 (1994) 3417-3418
18. Ades L., Mary J.Y., Robin M., et al. Long-term outcome after bone marrow transplantation for severe aplastic anemia. Blood 103 (2004) 2490-2497
19. Locatelli F., Bruno B., Zecca M., et al. Cyclosporin A and short-term methotrexate versus cyclosporin A as graft versus host disease prophylaxis in patients with severe aplastic anemia given allogeneic bone marrow transplantation from an HLA-identical sibling: results of a GITMO/EBMT randomized trial. Blood 96 (2000) 1690-1697
20. Storb R., Blume K.G., O'Donnell M.R., et al. Cyclophosphamide and antithymocyte globulin to condition patients with aplastic anemia for allogeneic marrow transplantations: the experience in four centers. Biol Blood Marrow Transplant 7 (2001) 39-44
21. Storb R., Anasetti C., Appelbaum F., et al. Marrow transplantation for severe aplastic anemia and thalassemia major. Semin Hematol 28 (1991) 235-239
22. Wysocki C.A., Panoskaltsis-Mortari A., Blazar B.R., and Serody J.S. Leukocyte migration and graft-versus-host disease. Blood 105 (2005) 4191-4199
23. Yanik G., and Cooke K.R. The lung as a target organ of graft-versus-host disease. Semin Hematol 43 (2006) 42-52
24. Uderzo C., Bonanomi S., Busca A., et al. Risk factors and severe outcome in thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Transplantation 82 (2006) 638-644
25. Satwani P., Harrison L., Morris E., Del Toro G., and Cairo M.S. Reduced-intensity allogeneic stem cell transplantation in adults and children with malignant and nonmalignant diseases: end of the beginning and future challenges. Biol Blood Marrow Transplant 11 (2005) 403-422
26. Aoudjhane M., Labopin M., Gorin N.C., et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia 19 (2005) 2304-2312
27. Nademanee A., Schmidt G.M., Parker P., et al. The outcome of matched unrelated donor bone marrow transplantation in patients with hematologic malignancies using molecular typing for donor selection and graft-versus-host disease prophylaxis regimen of cyclosporine, methotrexate, and prednisone. Blood 86 (1995) 1228-1234
28. Deeg H.J., Seidel K., Casper J., et al. Marrow transplantation from unrelated donors for patients with severe aplastic anemia who have failed immunosuppressive therapy. Biol Blood Marrow Transplant 5 (1999) 243-252
29. Sasazuki T., Juji T., Morishima Y., et al. Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. Japan Marrow Donor Program. N Engl J Med 339 (1998) 1177-1185
30. Flomenberg N., Baxter-Lowe L.A., Confer D., et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood 104 (2004) 1923-1930
31. Malcovati L., Porta M.G., Pascutto C., et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 23 (2005) 7594-7603
32. Miceli M.H., Dong L., Grazziutti M.L., et al. Iron overload is a major risk factor for severe infection after autologous stem cell transplantation: a study of 367 myeloma patients. Bone Marrow Transplant 37 (2006) 857-864
33. Zimring J.C., Hair G.A., Deshpande S.S., and Horan J.T. Immunization to minor histocompatibility antigens on transfused RBCs through crosspriming into recipient MHC class I pathways. Blood 107 (2006) 187-189
34. Passweg J.R., Perez W.S., Eapen M., et al. Bone marrow transplants from mismatched related and unrelated donors for severe aplastic anemia. Bone Marrow Transplant 37 (2006) 641-649